Skip to content

Study · Randomized controlled trial · n = 84 · 2015

11 results

Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.

Jia Z, Feng Z, Tian R, Wang Q, Wang L

Immunopharmacology and immunotoxicology1 Jan 2015Cited by 11 (Europe PMC)

PMID26250523 (opens in a new tab)DOI10.3109/08923973.2015.1069837 (opens in a new tab)PepBankPUB-26250523
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, adding thymosin alpha‑1 to routine treatment improved PaO2 compared with baseline and with placebo plus routine treatment.

    In plain wordsIn adults with a COPD flare-up, thymosin alpha‑1 plus routine care improved blood oxygen more than routine care plus placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePartial pressure of oxygen (PaO2)
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Partial pressures of oxygen (PaO2), PaCO2, and pulmonary function of the experimental group improved after treatment compared to that recorded prior to treatment and that observed for the control group (p < 0.01, both).
    2 context sentences
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, adding thymosin alpha‑1 to routine treatment improved PaCO2 compared with baseline and with placebo plus routine treatment.

    In plain wordsIn adults with a COPD flare-up, thymosin alpha‑1 plus routine care improved blood carbon dioxide more than routine care plus placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePartial pressure of carbon dioxide (PaCO2)
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Partial pressures of oxygen (PaO2), PaCO2, and pulmonary function of the experimental group improved after treatment compared to that recorded prior to treatment and that observed for the control group (p < 0.01, both).
    2 context sentences
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, adding thymosin alpha‑1 to routine treatment improved pulmonary function compared with baseline and with placebo plus routine treatment.

    In plain wordsIn adults with a COPD flare-up, thymosin alpha‑1 plus routine care improved lung function more than routine care plus placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePulmonary function
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Partial pressures of oxygen (PaO2), PaCO2, and pulmonary function of the experimental group improved after treatment compared to that recorded prior to treatment and that observed for the control group (p < 0.01, both).
    2 context sentences
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, CD4+ T cell count rose in both groups and rose more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, CD4 T cells rose in both groups, and rose more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ T cell count
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, serum IFN-gamma rose in both groups and rose more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, interferon-gamma rose in both groups, and rose more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum interferon-gamma
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, the CD4+/CD8+ ratio rose in both groups and rose more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, the CD4/CD8 T cell ratio rose in both groups, and rose more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+/CD8+ ratio
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, the IFN-gamma/IL-4 ratio rose in both groups and rose more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, the interferon-gamma to IL-4 ratio rose in both groups, and rose more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIFN-gamma/IL-4 ratio
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, CD8+ T cell count fell in both groups and fell more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, CD8 T cells fell in both groups, and fell more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCD8+ T cell count
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, IL-4 fell in both groups and fell more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, IL-4 fell in both groups, and fell more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInterleukin-4 (IL-4) level
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, IL-8 fell in both groups and fell more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, IL-8 fell in both groups, and fell more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInterleukin-8 (IL-8) level
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with acute exacerbation of COPD, LTB4 fell in both groups and fell more with thymosin alpha‑1 than with placebo.

    In plain wordsIn adults with a COPD flare-up, leukotriene B4 fell in both groups, and fell more with thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLeukotriene B4 (LTB4) level
    Study

    n = 84

    Comparator
    Placebo plus routine treatment
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, the above-mentioned indices of the experimental group improved significantly compared to the indices of the control group (p < 0.05 or 0.01).
    3 context sentences
    Summary · context
    The CD4(+) T cell count, serum interferon (IFN)-γ levels, and the ratios of CD4(+)/CD8(+) and IFN-γ/interleukin (IL)-4 increased in both groups (p < 0.01), while the CD8(+) T cell count and levels of IL-4, IL-8, and leukotrienes B4 (LTB4) decreased as expected (p < 0.01).
    Summary · context
    Eighty-four AECOPD patients were enrolled and randomized into an experimental group and a control group.
    Summary · context
    Additionally, the experimental group received subcutaneous injections of Tα1 while the control group received placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.